Abbott to close $21B Exact Sciences deal on March 23

Abbott (NYSE: ABT)+ announced today that it expects to close the acquisition of Exact Sciences on Monday, […]

Abbott (NYSE: ABT)+ announced today that it expects to close the acquisition of Exact Sciences on Monday, March 23, 2026.

The medtech giant said it received all regulatory clearances necessary to complete the deal. Abbott raised $20 billion in an offering of notes to finance the deal earlier this month.

In November 2025, Abbott agreed to acquire Exact Sciences for approximately $21 billion. Madison, Wisconsin–based Exact Sciences develops cancer screening and diagnostic tests. Its portfolio includes the flagship Cologuard, a non-invasive test to screen for colorectal cancer.

Read full article: https://www.massdevice.com/abbott-close-exact-sciences-deal-march-23/